U

University of Ottawa | University of Ottawa Heart Institute - Lipid Clinic

Research site

(Unclaimed)

Location

40 Ruskin St Room H4203, Ottawa, Ontario, Canada

Site insights

Top conditions

Top treatments

Rivaroxaban

AOC 1020

Vericiguat

Tucatinib

levofloxacin

Paclitaxel

RK0202

Tenofovir Alafenamide

Albutein

Vinorelbine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 77 total trials

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (Galileo)

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple d...

Enrolling

Myotonic Dystrophy Type 1 (DM1)

Drug: Placebo

Drug: VX-670

A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema (Meerkat)

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Active, not recruiting

Uveitic Macular Edema

Other: Sham

Drug: Vamikibart

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE)

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Explora...

Enrolling

Muscular Dystrophy, Landouzy Dejerine

Fascioscapulohumeral Muscular Dystrophy

Drug: Placebo

Drug: AOC 1020

Phase 2 Open-label Extension Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE-OLE)

A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, and Pharmacokinetics of AOC 1020 Administered Intraven...

Invitation-only

Muscular Dystrophy, Landouzy Dejerine

Fascioscapulohumeral Muscular Dystrophy

Drug: AOC 1020

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and...

Active, not recruiting

AML

Bone Marrow Transplant

Drug: Iomab-B

Drug: Conventional Care